Chronic Respiratory Diseases Treatment Market Analysis

  • Report ID: 1121
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Respiratory Disorders Treatment Segmentation

The respiratory disorders treatment market is further segmented by disease type, drug class, route of administration, distribution channel and region. Disease type segment is further segmented into asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and Others. The increasing pool of patients of Asthma coupled with its high prevalence is expected to drive the market. Moreover, the popularity of inhalational type of drugs is rising on the back of its fast action and quick relief comparing to the conventional dosage forms. Thereby, the growth in these segments is expected to drive the respiratory disorders treatment market as well.

The high prevalence of diseases such as Asthma and COPD has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the respiratory disorders treatment market is expected to grow notably over the forecast period. 

Our in-depth analysis of the global market includes the following segments:

          By Disease Type

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others

          By Drug Type

  • Corticosteroids
  • Bronchodilators
  • Monoclonal Antibodies
  • Antibiotics
  • Mucolytic Agents
  • Leukotriene Modifiers
  • Others

          By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

          By Route of Administration

  • Parenteral
  • Oral
  • Inhalational

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of respiratory disorders treatment is assessed at USD 121.16 billion.

Respiratory Disorders Treatment Market size was valued at USD 115.09 billion in 2024 and is expected to reach USD 251.57 billion by 2037, registering around 6.2% CAGR during the forecast period i.e., between 2025-2037.

North America industry is anticipated to hold largest revenue share by 2037, led by increased awareness among the people about the respiratory diseases and the supporting government policies.

The major players in the market are Mylan N.V., Teva PharmaceuticalIndustries Ltd., Sunovion Pharmaceuticals Inc., Merck & Co., Inc., BoehringerIngelheim Pharmaceuticals, Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Regeneron Pharmaceuticals, Inc., Grifols, S.A., Pfizer Inc., and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos